The share of the population with overweight in the United States was forecast to continuously increase between 2024 and 2029 by in total 1.6 percentage points. After the fifteenth consecutive increasing year, the overweight population share is estimated to reach 77.43 percent and therefore a new peak in 2029. Notably, the share of the population with overweight of was continuously increasing over the past years.Overweight is defined as a body mass index (BMI) of more than 25.The shown data are an excerpt of Statista's Key Market Indicators (KMI). The KMI are a collection of primary and secondary indicators on the macro-economic, demographic and technological environment in up to 150 countries and regions worldwide. All indicators are sourced from international and national statistical offices, trade associations and the trade press and they are processed to generate comparable data sets (see supplementary notes under details for more information).Find more key insights for the share of the population with overweight in countries like Canada and Mexico.

In 2022, it was estimated that around 38 percent of adults in the United States aged 18 to 44 years did not get enough sleep. In comparison, around 28 percent of adults aged 65 years and older had insufficient sleep. Getting less than seven hours of sleep every day is considered insufficient sleep. Insufficient sleep in the United States The percentage of adults in the United States reporting insufficient sleep has remained relatively unchanged over the past decade. However, the year 2020 saw an unusual drop in the share of adults reporting not getting enough sleep, likely due to people working less or from home due to the COVID-19 pandemic. In 2022, around 38 percent of men and 36 percent of women in the U.S. reported not getting enough sleep. Getting sufficient sleep can reduce stress and improve mood, lower the risk of chronic disease, and help to maintain a healthy weight. How common are sleeping problems? A survey of U.S. adults from 2022 found that only 46 percent reported having no trouble sleeping, while 15 percent had trouble falling asleep, 28 percent trouble staying asleep, and 11 percent trouble falling and staying asleep. Common reasons for having a poor night’s sleep or trouble sleeping include needing to use the bathroom, physical discomfort, and being too hot. To improve sleep habits, the CDC recommends going to bed and getting up at the same time every day, regularly exercising, avoiding alcohol before bed and caffeine in the afternoon and evening, and keeping the bedroom cool, quiet, and relaxing.

According to Cognitive Market Research, the Global Opioids Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

  The global opioid market will expand significantly by XX% CAGR between 2024 and 2030.
  The Pain Relief segment accounts for the largest market share and is anticipated to a healthy growth over the approaching years.
  The hospital pharmacies had a market share of about XX% in 2023.
  The Extended Release /Long-Acting Opioids holds the largest share and is expected to grow in the coming years as well.
  The injectable segment is the market's largest contributor and is anticipated to expand at a CAGR of XX% during the projected period.
  The oxycodone segment holds the largest share and is expected to grow in the coming years as well.
  North America region dominated the market and accounted for the highest revenue of XX% in 2023 and it is projected that it will grow at a CAGR of XX% in the future.

Market Dynamics of the Opioids

Rising prevalence of chronic pain conditions globally

The increased prescription of painkillers during post-operative procedures and an increase in patients with terminally chronic pain or diseases including HIV, and severe cough brought on by lung infections are two causes that are anticipated to increase opioid use as a pain reliever. Chronic pain affects an estimated 20% of the global population, with conditions such as arthritis, cancer, and lower back pain contributing to the growing demand for effective pain management solutions. In the past, it resulted in a demand surge for opioids and boosted growth. Another factor for the growth of the opioid drug market is the spike in the number of surgeries. According to the National Health Interview Survey (NHIS) conducted by the Centers for Disease Control and Prevention (CDC) in 2019, the prevalence of high-impact chronic pain in the United States was 7.4 percent.

(Source-https://www.cdc.gov/nchs/data/databriefs/db390-H.pdf)

The aging population’s vulnerability is at high risk of chronic diseases such as cardiovascular diseases, arthritis, and cancer due to the high comorbid conditions. Declining fertility and mortality rates are some factors contributing to the geriatric population's rise. The impact of chronic pain increases with age and is highest among adults aged 65 years and above. Therefore, the rising geriatric population is anticipated to increase the demand for opioid drugs to manage chronic pain. According to the World Health Organization (WHO), the geriatric population increased from 1.0 million in 2020 to 1.4 million in 2021.

(Source-https://www.who.int/news-room/fact-sheets/detail/ageing-and-health)

Opioid addiction and its side effects pose significant challenges to the market

One of the major challenges for this market is the high potential for abuse and addiction, physicians have scaled back their pain management prescriptions, decreasing global scales. The rising prevalence of opioid abuse is expected to stifle market growth, as practitioners are hesitant to prescribe opioids as pain relievers. The patient may become tolerant and need more and more drugs to achieve the effect of smoothing the pain. Moreover, using opioids for an extended period can develop a dependency, and after leaving the drug, the patient may suffer from withdrawal symptoms such as anxiety, irritability, drug cravings, tremors (shaking), and others. The heightened regulatory scrutiny has resulted in stricter guidelines for prescribing opioids, impacting accessibility for patients in genuine need of pain relief. Regulatory changes often aim to strike a balance between ensuring access for patients and preventing misuse. The forecasted period illustrates a decrease in the opioid market growth due to the adversities and the negative effects of opioids. Researchers and experts have considered this and are making constant efforts to reduce and minimize the negative side effects of opioids. As per the record, drug overdose in the year 2018, had 657 deaths.

(Source-https://www.mass.gov/doc/opioid-related-overdose-deaths-among-ma-residents-august-2018/download)

Furthermore, the Millennium Health's Signals report (2020) revealed that there was a rise in non-prescribe...

The mortality rate from influenza in the United States is by far highest among those aged 65 years and older. During the 2023-2024 flu season, the mortality rate from influenza for this age group was around 32.1 per 100,000 population. The burden of influenza The impact of influenza in the U.S. varies from season to season, but in the 2023-2024 flu season, there were an estimated 40 million cases. These cases resulted in around 470,000 hospitalizations. Although most people recover from influenza without requiring medical treatment, the disease can be deadly for young children, the elderly, and those with weakened immune systems or chronic illnesses. During the 2023-2024 flu season, around 28,000 people in the U.S. lost their lives due to influenza. Impact of vaccinations The most effective way to prevent influenza is to receive an annual vaccination at the beginning of flu season. Flu vaccines are safe and can greatly reduce the burden of the disease. During the 2022-2023 flu season, vaccinations prevented around 2,479 deaths among those aged 65 years and older. Although flu vaccines are usually cheap and easily accessible, every year a large share of the population in the U.S. still does not get vaccinated. For example, during the 2022-2023 flu season, only about 35 percent of those aged 18 to 49 years received a flu vaccination.

According to Cognitive Market Research, the Cardiovascular Devices Market Size will be USD XX Billion in 2024 and is set to achieve a market size of USD XX Billion by the end of 2033 growing at a CAGR of XX% from 2025 to 2033.

• North America held largest share of XX% in the year 2024 • Europe held share of XX% in the year 2024 • Asia-Pacific held significant share of XX% in the year 2024 • South America held significant share of XX% in the year 2024 • Middle East and Africa held significant share of XX% in the year 2024

Market Dynamics of the Cardiovascular Devices Market Key Drivers for the Cardiovascular Devices Market

Rising in cardiovascular diseases prevalence fuels the cardiovascular devices market 

The cardiovascular disorders are the group of medical condition where it affects heart and blood vessels, encompassing various diseases and disorder that affects on the circulatory system. The cardiac devices help to maintain the regular heart function and blood flow in patients with weak improper function of heart. The global cardiac device market shows significant growth, largely driven by increase in prevalence of heart disease. The cardiovascular disease treatment is costly in terms of healthcare services. Now the conditions like coronary artery disease and heart failure are becoming increasingly prevalent, so there is increase in demand of coronary stents and crucial devices which are used to treat the cardiovascular diseases. Also, the global population increases and continues to age the incidence of chronic heart condition is expected to rise. This demographic condition is shift further and results in growing need of cardiovascular devices that can treat the wide range of heart diseases. For instance, according to centers for disease control and prevention (CDC) in the United States heart diseases is the major cause of death for both men and women and people of most racial and ethnic groups. They said that one person dies every 33 seconds from cardiovascular disease. In 2022, 702,880 people died from heart disease. That is equivalent to 1 in every 5 deaths (Source - https://www.cdc.gov/heart-disease/index.html ) Thus, due to the rising patients in cardiovascular disease segment and the advancement in technology boosts the cardiovascular devices market. Rising awareness of health also helps to drive this market.

The rise in healthcare expenditure drives the Cardiovascular Devices Market

Globally the health awareness is increasing vastly countries monitor their health of the population related to cardiac health preferably. They also focus on the expansion of healthcare expenditure where the people also now get aware about their health. The advancement in technology of medical devices increases the patient convenience and now they can get treatment and monitor their health more effectively. Each country now spends on their healthcare expenditure to provide healthcare service to all needy people who cannot afford the costly devices. For instance, U.S. health expenditure grew by 4.1% in 2022 to $4.5 trillion or $13,493 per capita. This rate of growth is similar to pre-pandemic levels (4.1% in 2019). While government expenditure to contain the pandemic resulted in significant growth in NHE, these expenditures fell sharply in 2021 while use of medical goods and services recovered. By 2022, overall trends in health expenditure more closely approximated that of the pre-pandemic era. (Source - https://www.ama-assn.org/about/research/trends-health-care-spending ) The market for cardiovascular devices is expected to grow as a result of rising healthcare costs. The total amount spent on healthcare-related services, goods, and activities over a given time period usually at the individual, community, national, or international level is referred to as healthcare expenditures. Adoption of cutting-edge cardiovascular technologies and devices is made possible by increased healthcare spending, which improves patient outcomes and care. For Instance, in Europe the spending on cardiovascular disease is greater than the spending done in Germany. CVD is estimated to cost the EU €282 billion annually, with health and long-term care accounting for €155 billion (55%), equaling 11% of EU-health exp...

The burden of influenza in the United States can vary from year to year depending on which viruses are circulating, how many people receive an influenza vaccination, and how effective the vaccination is in that particular year. During the 2023-2024 flu season, around 28,000 people lost their lives to the disease. Although most people recover from influenza without needing medical care, the disease can be deadly among young children, the elderly, and those with weakened immune systems or chronic illnesses. Deaths due to influenza Even though most people recover from influenza without medical care, influenza and pneumonia can be deadly, especially for older people and those with certain preexisting conditions. Influenza is a common cause of pneumonia and although most cases of influenza do not develop into pneumonia, those that do are often more severe and more deadly. Deaths due to influenza are most common among the elderly, with a mortality rate of around 32 per 100,000 population during the 2023-2024 flu season. In comparison, the mortality rate for those aged 50 to 64 years was 9.1 per 100,000 population. Flu vaccinations The most effective way to prevent influenza is to receive an annual influenza vaccination. These vaccines have proven to be safe and are usually cheap and easily accessible. Nevertheless, every year a large share of the population in the United States still fails to get vaccinated against influenza. For example, in the 2022-2023 flu season, only 35 percent of those aged 18 to 49 years received a flu vaccination. Unsurprisingly, children and the elderly are the most likely to get vaccinated. It is estimated that during the 2022-2023 flu season, vaccinations prevented over 929 thousand influenza cases among children aged 6 months to 4 years.

According to Cognitive Market Research, the Global Therapeutic Drug Monitoring Market Size will be USD XX Billion in 2024 and is set to achieve a market size of USD XX Billion by the end of 2033 growing at a CAGR of XX% from 2025 to 2033.

• North America held largest share of XX% in the year 2024 • Europe held share of XX% in the year 2024 • Asia-Pacific held significant share of XX% in the year 2024 • South America held significant share of XX% in the year 2024 • Middle East and Africa held significant share of XX% in the year 2024 Market Dynamics of Therapeutic Drug Monitoring Market Key Drivers for Therapeutic Drug Monitoring Market

Rising prevalence of chronic diseases fueling the market growth  

The rising incidence of chronic diseases is a major growth driver for the Therapeutic Drug Monitoring (TDM) market. Chronic diseases such as cardiovascular disease, cancer, diabetes, and neurological disorders are on the rise worldwide owing to aging populations, lifestyle modifications, and environmental factors. These conditions usually need to be treated for extended periods of time, and most of the medications employed to treat them have small therapeutic windows, i.e., the margin between a therapeutic dose and a toxic dose is small. In patients with chronic illnesses, having the correct drug concentration in the blood is very important to make the drug work effectively while reducing possible side effects or toxicity. TDM enables health care professionals to continuously monitor and change drug dosing according to patients' individual responses, which results in improved clinical outcomes. It is particularly relevant in conditions such as cancer, where the chemotherapy drugs have to be closely monitored to prevent toxicity. For instance, in 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. (Source - https://pubmed.ncbi.nlm.nih.gov/36633525/ ) In cardiovascular disease, where anticoagulants require accurate dosing to prevent bleeding or clotting. In addition, the chronic nature of disease management entails the fact that patients can develop changes in drug metabolism with time, which requires constant changes in their treatment regimen. TDM is responsible for making such adaptations possible, so that drugs remain efficacious as the patient's condition progresses. For instance, coronary heart disease is the most prevalent form of heart disease. It claimed 371,506 lives in 2022.Approximately 1 in 20 adults aged 20 and older have CAD (approximately 5%). In 2022, roughly 1 death out of 5 due to cardiovascular diseases (CVDs) occurred in adults under 65 years of age. (Source - https://www.cdc.gov/heart-disease/data-research/facts-stats/index.html ) With the rising incidence of chronic diseases, there is a growing need for customized treatment strategies, which is also driving the TDM market forward. Tailoring medication regimens according to the needs of individuals increases patient safety, increases therapeutic effectiveness, and enhances the quality of care for patients with chronic diseases.

Key Restraints for Therapeutic Drug Monitoring Market

Operational barriers faced in conducting therapeutic drug monitoring tests hamper the market 

The development of the Therapeutic Drug Monitoring (TDM) market is hindered by various operational and technological challenges, which are crucial in limiting its growth. The main challenge is that it is challenging to ensure effective sample procurement, storage, and transport, particularly when using sophisticated technology such as chemiluminescence immunoassays, High-Performance Liquid Chromatography (HPLC), and multiplex flow immunoassays (MFI). These advanced technologies need to be handled with accuracy to prevent cross-contamination and preserve sample integrity, which is hard to control, particularly under resource constraints. Additionally, preserving and operating high-tech immunoassay devices, especially ones that are dedicated to analyzing just one type of sample, is extremely costly. Clinical labs would have to make significant investments in specialized hardware, and running these technologies can prove to be highly expensive, especially in developing nations where the infrastructure for healthca...

According to Cognitive Market Research, the Global Heparin Market Size is USD XX Million in 2024 and is set to achieve a market size of USD XX Million by the end of 2033 growing at a CAGR of XX% from 2024 to 2033.

North America held largest share of XX% in the year 2024 
Europe held share of XX% in the year 2024 
Asia-Pacific held significant share of XX% in the year 2024 
South America held significant share of XX% in the year 2024
Middle East and Africa held significant share of XX% in the year 2024 

Market Dynamics of Heparin Market

Key Drivers for Heparin Market

Increasing Prevalence of Cardiovascular Diseases is inflating the heparin market.

Chronic blood diseases cases are increasing exponentially and are expected to propel the global antiplatelet drugs market. Chronic disease prevalence increase is due to drive the market. The increase in the incidence of cardiovascular diseases is one of the key drivers of the growth rate of the antiplatelet drugs market. Cardiovascular disease is the leading cause of mortality in both developed and developing economies.

It is estimated by the Centers for Disease Control and Prevention (CDC) that more than 8,00,000 people in the United States pass away every year due to stroke and other cardiovascular diseases. For instance, a World Health Organization (WHO) study has reported that cardiovascular diseases (CVDs) are responsible for approximately 31% of total patient deaths every year. For instance, in 2022, as noted in a National Library of Medicine study, cardiovascular diseases (CVD) were responsible for approximately 19.8 million deaths globally, necessitating the effective treatment of heparin in controlling thrombosis and mitigating mortality rates of CVD-related complications. The increasing rate of CVDs is a major factor behind the need for heparin: Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a major cause of cardiovascular mortality worldwide. VTE risk doubles every decade after the age of 40, and is also very high among inpatients, with the incidence of 10 to 20 cases per 1,000 admissions. Atrial fibrillation, a prevalent cardiac arrhythmia, occurs in an estimated 12.1 million Americans by 2030, and this boosts the demand for anticoagulant drugs such as heparin. These highlights the imperative function of heparin in treating and preventing cardiovascular disease-related complications, thus fueling market expansion.

Rising number of geriatric populations increases CVD which in turn increases the usage of heparin and the market is expanding.

Growing geriatric population globally is expected to support heparin drugs demand since this group is susceptible to heart diseases. The population of individuals over 65 years is expected to double in the future years. The old-aged individuals are susceptible to many chronic diseases like cardiovascular diseases, which can encourage the demand for heparin drugs globally. There were approximately 382 million aged people, aged 60 years and older, in the world in 2017 and it is projected to grow to 2.1 billion by 2050, as per the United Nations. Older adults with cardiovascular disease (CVD) often face the challenge of managing multiple chronic or multimorbid conditions, leading to a significant drug burden that complicates their treatment. With the prevalence of multimorbidity ranging from 30% to 83% in individuals aged 65 and older, cardiovascular comorbidities are frequently reported as the most common combination of chronic diseases. This situation is further exacerbated by issues such as functional decline and complex geriatric syndromes (GSs), which are major concerns in the management of this population. Notably, polypharmacy, defined as the simultaneous use of five or more medications, affects 26.3% to 40% of older adults, with excessive polypharmacy impacting around 10%. The incidence of polypharmacy can reach alarming rates, with studies indicating a 53% to 87% incidence over three years. The presence of geriatric syndromes, which can affect 10% to 60% of older adults, significantly contributes to declines in functional status and quality of life, increased hospital admissions, and higher mortality rates. Additionally, frailty, characterized by a reduced physiological reserve and increased vulnerability to stressors, affects 10% of older adults, with rates as high as 60% in those with severe ...

NOTE: This dataset replaces two previous ones. Please see below. Chicago residents who are up to date with COVID-19 vaccines, based on the reported address, race-ethnicity, sex, and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). “Up to date” refers to individuals who meet the CDC’s updated COVID-19 vaccination criteria based on their age and prior vaccination history. For surveillance purposes, up to date is defined based on the following criteria: People ages 5 years and older: · Are up to date when they receive 1+ doses of a COVID-19 vaccine during the current season. Children ages 6 months to 4 years: · Children who have received at least two prior COVID-19 vaccine doses are up to date when they receive one additional dose of COVID-19 vaccine during the current season, regardless of vaccine product. · Children who have received only one prior COVID-19 vaccine dose are up to date when they receive one additional dose of the current season's Moderna COVID-19 vaccine or two additional doses of the current season's Pfizer-BioNTech COVID-19 vaccine. · Children who have never received a COVID-19 vaccination are up to date when they receive either two doses of the current season's Moderna vaccine or three doses of the current season's Pfizer-BioNTech vaccine. This dataset takes the place of two previous datasets, which cover doses administered from December 15, 2020 through September 13, 2023 and are marked has historical: - https://data.cityofchicago.org/Health-Human-Services/COVID-19-Daily-Vaccinations-Chicago-Residents/2vhs-cf6b - https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccinations-by-Age-and-Race-Ethnicity/37ac-bbe3. Data Notes: Weekly cumulative totals of people up to date are shown for each combination of race-ethnicity, sex, and age group. Note that race-ethnicity, age, and sex all have an option for “All” so care should be taken when summing rows. Coverage percentages are calculated based on the cumulative number of people in each race-ethnicity/age/sex population subgroup who are considered up to date as of the week ending date divided by the estimated number of people in that subgroup. Population counts are obtained from the 2020 U.S. Decennial Census. Actual counts may exceed population estimates and lead to coverage estimates that are greater than 100%, especially in smaller demographic groupings with smaller populations. Additionally, the medical provider may report incorrect demographic information for the person receiving the vaccination, which may lead to over- or underestimation of vaccination coverage. All coverage percentages are capped at 99%. Weekly cumulative counts and coverage percentages are reported from the week ending Saturday, September 16, 2023 onward through the Saturday prior to the dataset being updated. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. The Chicago Department of Public Health uses the most complete data available to estimate COVID-19 vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Individuals may receive vaccinations that are not recorded in the Illinois immunization registry, I-CARE, such as those administered in another state, causing underestimation of the number individuals who are up to date. Inconsistencies in records of separate doses administered to the same person, such as slight variations in dates of birth, can result in duplicate records for a person and underestimate the number of people who are up to date.

According to Cognitive Market Research, the global Polypill Products market size will be USD 34182.8 million in 2025. It will expand at a compound annual growth rate (CAGR) of 3.00% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 12647.64 million in 2025 and will grow at a compound annual growth rate (CAGR) of 1.8% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 9913.01 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 8203.87 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.5% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 1298.95 million in 2025 and will grow at a compound annual growth rate (CAGR) of 3.3% from 2025 to 2033.
Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 1367.31 million in 2025 and will grow at a compound annual growth rate (CAGR) of 3.5% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 752.02 million in 2025 and will grow at a compound annual growth rate (CAGR) of 2.7% from 2025 to 2033.
Thermoplastic category is the fastest growing segment of the Polypill Products industry

Market Dynamics of Polypill Products Market

Key Drivers for Polypill Products Market

Increasing Prevalence of Cardiovascular Diseases (CVDs) to Boost Market Growth

Cardiovascular diseases (CVDs), including hypertension, heart attacks, and strokes, are among the leading causes of death worldwide. According to the World Health Organization (WHO), approximately 17.9 million people die from CVDs each year, accounting for 31% of all global deaths. In the United States, heart disease caused 702,880 deaths in 2022, representing 1 in every 5 deaths. Between 2019 and 2020, heart disease cost the U.S. healthcare system about $252.2 billion. Coronary heart disease (CAD) remains the most common type of heart disease, claiming 371,506 lives in 2022. Additionally, about 1 in 20 adults aged 20 and older (around 5% of the adult population) have CAD. Polypills have proven to be highly effective in managing CVDs by combining medications such as statins, beta-blockers, ACE inhibitors, and aspirin into a single dose. This simplifies treatment regimens and improves patient adherence. Clinical studies have shown that when taken consistently, polypills can reduce the risk of major cardiovascular events by up to 50%, leading to increased adoption among healthcare providers and patients.

https://www.cdc.gov/heart-disease/data-research/facts-stats/index.html/./

Growing Geriatric Population to Boost Market Growth

The global population aged 65 years and older is growing rapidly. According to the United Nations, the number of people in this age group is expected to double by 2050, reaching over 1.5 billion. By 2030, 1 in 6 people worldwide will be aged 60 years or older. The population aged 60 and above is projected to increase from 1 billion in 2020 to 1.4 billion by 2030. By 2050, the global population of people aged 60 and older is expected to double to 2.1 billion. The number of people aged 80 years and older is anticipated to triple between 2020 and 2050, reaching 426 million. In 2020, the number of people aged 60 years and older surpassed the population of children under 5 years. Between 2015 and 2050, the proportion of the global population aged over 60 years is projected to nearly double from 12% to 22%. Older adults are more prone to developing multiple chronic diseases, such as cardiovascular diseases (CVD), diabetes, and high cholesterol, which often require complex medication regimens. Polypills simplify medication schedules for elderly patients, enhancing adherence and reducing the risk of missed doses or medication errors, thereby driving market growth.

https://www.who.int/news-room/fact-sheets/detail/ageing-and-health./

Restraint Factor for the Polypill Products Market

Complex Regulatory Approval Process, Will Limit Market Growth

Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have strict guidelines for approving fixed-dose combination (FDC) drugs, including polypills. Since polypills combine multiple activ...